Fig. 10

Inhibition of METTL3 blocks SRPK1‑induced cancer growth in vitro and in vivo. A The METTL3 inhibitor (STM2457) suppressed the mRNA and protein levels of SRPK1. B STM2457 inhibited SRPK1-induced hypercell viability, as detected by EdU assays. C Quantification of the EdU assay in SRPK1-overexpressing cells treated with STM2457. D Glucose uptake and lactate generation were measured in SRPK1-overexpressing cells treated with STM2457. E A diagram showing the procedure of the in vivo experiment. F Representative images of the xenograft tumours from three groups. G, H Tumour weight and volume in the SRPK1-overexpression and control groups without or with STM2457 treatment. I Western blot assay of SRPK1, hnRNPA1, PKM1, PKM2 and PCNA protein levels. Data are illustrated as the mean (± SD) of three separate experiments. Two-way ANOVA and unpaired t-tests were carried out to validate the statistical significance. *P < 0.05; **P < 0.01; ***P < 0.001